Sofosbuvir/velpatasvir with ribavirin improves liver, renal function in chronic HCV
Click Here to Manage Email Alerts
Key takeaways:
- Nearly 97% of patients achieved sustained virologic response at 12 weeks after treatment with sofosbuvir/velpatasvir with ribavirin.
- Both renal and liver function improved with treatment.
BOSTON — A regimen of sofosbuvir/velpatasvir with ribavirin was effective among patients with refractory chronic hepatitis C virus with liver cirrhosis and chronic kidney disease, according to data presented at The Liver Meeting.
Researchers in China investigated the safety and efficacy of a 12-week regimen of sofosbuvir/velpatasvir with ribavirin among 65 patients (mean age, 52.3 years; 77% men) with refractory chronic HCV, liver cirrhosis and chronic kidney disease (CKD). The dosage of ribavirin for each patient was determined by their weight and renal function.
The primary endpoint was change in renal function during the study, and other outcomes included sustained virologic response 12 weeks after treatment (SVR12), liver function and adverse events.
According to study results, 75.4% (n = 49) of patients were stage 2 CKD at baseline, while 18.5% (n = 12) were stage 3, 3% (n = 2) were stage 4 and 3.1% (n = 2) were stage 5. Twenty-seven patients (41.54%) had compensated cirrhosis and 38 (58.46%) had decompensated cirrhosis.
Following treatment, 96.9% (n = 63) of patients achieved SVR12 and 21.5% (n = 14) improved to CKD stage 1. Researchers also reported significant decreases in alanine transaminase and aspartate aminotransferase.
During treatment, 38.5% (n = 25) of patients reported adverse events, which included hemolysis, pruritus, rash, dizziness and fatigue. No serious adverse events were reported.
The findings demonstrated that treating chronic HCV, liver cirrhosis and CKD with a regimen of sofosbuvir/velpatasvir with ribavirin was effective and well-tolerated by patients.
Collapse
Yang Y, et al. Sofosbuvir/velpatasvir with or without ribavirin for chronic hepatitis C virus infected patients with liver cirrhosis and chronic kidney disease: Real-world data from Southwest China. Presented at: The Liver Meeting; Nov. 10-14, 2023; Boston (hybrid meeting).
Click Here to Manage Email Alerts